Impact
NIMA Partners – SUCCESS PAGE – September 08, 2026
NIMA has developed a handheld sensor that can test a food sample for gluten contamination in approximately three minutes with 99% accuracy.
NIMA has developed a handheld sensor that can test a food sample for gluten contamination in approximately three minutes with 99% accuracy.
A first-in-class oral therapy for cancer, neuroinflammatory, and autoimmune disease with both FDA Fast Track and Orphan Drug designations
How leading scientists determine which discoveries have the potential to become meaningful new therapies.
A European aesthetics company designed to capitalize on changing consumers, advances in technology, and demand for more affordable treatments
Precision BioSciences (NASDAQ: DTIL) is working to create a future where devastating genetic diseases can be treated at their source
PortIO is the first intraosseous port that provides long-term vascular access, maintenance-free operation, fewer infections, and broad clinical applicability
A first-in-class oral therapy for cancer, neuroinflammatory, and autoimmune disease with both FDA Fast Track and Orphan Drug designations
Brook is giving health systems the technology, clinical teams, and infrastructure to support patients beyond the traditional office visit
Peak Altitude Partners helps family offices identify, evaluate, and manage institutional-quality private market opportunities
Kesmalea is developing an oral therapeutic designed to selectively eliminate a protein strongly associated with Alzheimer’s progression
A first-in-class oral therapy for cancer, neuroinflammatory, and autoimmune disease with both FDA Fast Track and Orphan Drug designations
Kesmalea is developing an oral therapeutic designed to selectively eliminate a protein strongly associated with Alzheimer’s progression